key: cord-1052174-87fruomm
authors: Chu, Hin; Chan, Jasper Fuk-Woo; Wang, Yixin; Yuen, Terrence Tsz-Tai; Chai, Yue; Hou, Yuxin; Shuai, Huiping; Yang, Dong; Hu, Binjie; Huang, Xiner; Zhang, Xi; Cai, Jian-Piao; Zhou, Jie; Yuan, Shuofeng; Kok, Kin-Hang; To, Kelvin Kai-Wang; Chan, Ivy Hau-Yee; Zhang, Anna Jinxia; Sit, Ko-Yung; Au, Wing-Kuk; Yuen, Kwok-Yung
title: Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19
date: 2020-04-09
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa410
sha: c4916befbbc078c66427394101459ee932ab3bc4
doc_id: 1052174
cord_uid: 87fruomm

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging coronavirus that has resulted in nearly 1,000,000 laboratory-confirmed cases including over 50,000 deaths. Although SARS-CoV-2 and SARS-CoV share a number of common clinical manifestations, SARS-CoV-2 appears to be highly efficient in person-to-person transmission and frequently cause asymptomatic infections. However, the underlying mechanism that confers these viral characteristics on high transmissibility and asymptomatic infection remain incompletely understood. METHODS: We comprehensively investigated the replication, cell tropism, and immune activation profile of SARS-CoV-2 infection in human lung tissues with SARS-CoV included as a comparison. RESULTS: SARS-CoV-2 infected and replicated in human lung tissues more efficiently than that of SARS-CoV. Within the 48-hour interval, SARS-CoV-2 generated 3.20 folds more infectious virus particles than that of SARS-CoV from the infected lung tissues (P<0.024). SARS-CoV-2 and SARS-CoV were similar in cell tropism, with both targeting types I and II pneumocytes, and alveolar macrophages. Importantly, despite the more efficient virus replication, SARS-CoV-2 did not significantly induce types I, II, or III interferons in the infected human lung tissues. In addition, while SARS-CoV infection upregulated the expression of 11 out of 13 (84.62%) representative pro-inflammatory cytokines/chemokines, SARS-CoV-2 infection only upregulated 5 of these 13 (38.46%) key inflammatory mediators despite replicating more efficiently. CONCLUSIONS: Our study provided the first quantitative data on the comparative replication capacity and immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung tissues. Our results provided important insights on the pathogenesis, high transmissibility, and asymptomatic infection of SARS-CoV-2.

genome of SARS-CoV-2 was most homologous to Chinese horseshoe bat SARS-related coronaviruses and was speculated to have jumped into a yet unknown wild animal being traded in a Wuhan wet market in China where this pandemic agent was first detected in the environmental samples. 2, 3 Apparently more efficient person-to-person transmission than 2003 SARS was soon noticed in the settings of family, church, community, cruise ship, nursing home, and hospital. [4] [5] [6] [7] [8] Despite the much lower crude fatality rate of COVID-19 (0.25% to 5%) than that of SARS (about 10%), the high number of patients affected in this ongoing pandemic due to a complete lack of population herd immunity resulted in a staggering number of deaths. 9 The clinical manifestations of COVID-19 can vary from asymptomatic virus shedding among household contacts, mild upper respiratory tract infection, acute asymptomatic walking pneumonia, to symptomatic pneumonia with bilateral multifocal ground-glass opacities on lung imaging studies, and severe pneumonia with acute respiratory distress syndrome and multiorgan failure. 10 Though animal models of non-human primate, human angiotensin-converting enzyme 2 (ACE2) transgenic mouse, and golden Syrian hamster successfully challenged by SARS-CoV-2 have recently been reported, studies on the pathogenesis of COVID-19 in human subjects are still largely lacking. [11] [12] [13] While bronchoalveolar lavage was frequently performed in severe COVID-19 patients for making a virological diagnosis, transbronchial or open lung biopsy for detecting the histopathological changes and host response in the human lung induced by SARS-CoV-2 was almost never performed for understanding the pathogenesis in these severe patients with respiratory failure.

Post-mortem examinations were also rarely performed until multi-organ failure developed A c c e p t e d M a n u s c r i p t 7 after weeks of intensive care by intubation and ventilation. 14 In this study, we used ex vivo human lung tissue challenged by SARS-CoV-2 with SARS-CoV as control to quantitatively characterise the viral kinetics, cell type tropism, virus protein expression, and host cytokine/chemokine responses. It is notable that the ex vivo lung tissue from each individual donor patient can be divided into two parts for parallel challenge by the test SARS-CoV-2 and the control SARS-CoV. Thus this ex vivo lung model system provides a unique opportunity for side by side comparison of the virological and host response characteristics that clinical studies on patients or animal models cannot achieve. The findings are important in understanding the relatively more efficient transmissibility of COVID-19 and the innate immune mechanism behind this phenomenon.

SARS-CoV-2 HKU-001a (GenBank accession number MT230904) was isolated from the nasopharyngeal aspirate of a laboratory-confirmed COVID-19 patient in Hong Kong as previously described. 15 SARS-CoV GZ50 (GenBank accession number AY304495) was an archived clinical isolate at Department of Microbiology, HKU. Both SARS-CoV-2 and SARS-CoV were propagated and titered in VeroE6 cells with plaque assays as previously described. 15, 16 All experiments involving infectious SARS-CoV-2 and SARS-CoV followed the approved standard operating procedures of our Biosafety Level 3 facility at the

A c c e p t e d M a n u s c r i p t 8

Human lung tissues for ex vivo studies were obtained from patients undergoing surgical operations at Queen Mary Hospital, Hong Kong as we previously described. 17 All donors gave written consent as approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UW13-364). The freshly obtained lung tissues were processed into small rectangular pieces and were rinsed with advanced Dulbecco's Modified Eagle's Medium (DMEM)/F12 medium (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 2mM of 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES) (Gibco), 1×GlutaMAX (Gibco), 100U/ml penicillin, and 100μg/ml streptomycin. The specimens were infected with SARS-CoV-2 or SARS-CoV with an inoculum of 1×10 6 PFU/ml at 500µl per well. After 2h, the inoculum was removed and the specimens were washed with phosphate-buffered saline (PBS) 3 times. The infected human lung tissues were then cultured in 1.2ml of advanced DMEM/F12 medium with 2mM HEPES (Gibco), 1×GlutaMAX (Gibco), 100U/ml penicillin, 100μg/ml streptomycin, 20μg/ml vancomycin, 20μg/ml ciprofloxacin, 50μg/ml amikacin, and 50μg/ml nystatin.

Supernatants were collected at 2, 24, and 48 hours post-inoculation (hpi) for plaque assays.

The lung tissues were harvested at 2, 24, and 48hpi in RL buffer (Qiagen, Hilden, Germany) with DTT (Qiagen) for quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis or fixed in 10% formalin for immunostaining and immunohistochemistry studies.

Immunofluorescence staining and confocal microscopy were performed as previously described with slight modifications. 15, 18, 19 Briefly, infected human lung tissue samples were harvested and fixed overnight using 10% formalin, and then processed with a TP1020 Leica A c c e p t e d M a n u s c r i p t 9 semi-enclosed benchtop tissue processor with serially increasing concentration of ethanol, xylene, and wax for 16h, before being embedded in wax. Formalin-fixed, paraffin-embedded human lung tissues were then sectioned at 4μm with a Thermo Fisher Scientific HM 355S rotary microtome. Tissue sections were fished and dried to fix on Thermo Fisher Scientific Superfrost Plus slides at 37 o C overnight before deparaffinising and immunofluorescence staining. Serially increasing concentrations of xylene and ethanol were applied for dewaxing.

In order to expose the viral nucleocapsid (N) antigens, the slides were heated with antigen unmasking solution (Vector Laboratories, Burlingame, CA, USA) in a pressure cooker for 90s. After blocking with serum-free protein block and Sudan black B, the slides were stained with an in-house mouse anti-SARS-CoV-2-N immune serum or an in-house mouse anti-SARS-CoV-N immune serum. The secondary antibody goat anti-mouse IgG H&L (Alexa Fluor® 488) was obtained from Thermo Fisher Scientific. Mounting was performed with the antifade mounting medium with DAPI (Vector Laboratories). Images were acquired with confocal microscopy using a ZEISS LSM710 system with the 20×objective as previously described. 20 Image fields were selected and processed with the ZEN software blue edition (ZEISS) at the resolution of 1024×1024 pixels. To quantify the relative fluorescence intensity, multiple images from infected human lung tissues of two representative donors were split into separate channels and the intensity of channel 488 nm was quantified with ImageJ.

Histology and immunohistochemistry staining were performed as previously described with slight modifications. 13 Briefly, fixed human tissues were processed, embedded, and cut to prepare 4μm tissue sections on glass slides. Slides were dewaxed with xylene and serially decreased concentrations of ethanol before staining. To detect SARS-CoV-2-N and SARS-A c c e p t e d M a n u s c r i p t 10 CoV-N antigens, tissue sections underwent the same antigen retrieval procedures as those of immunofluorescence staining, followed by blocking with 0.3% hydrogen peroxide for 30min to abolish the activity of any potential endogenous peroxidase. The slides were subsequently incubated with an in-house mouse anti-SARS-CoV-2-N immune serum or an in-house mouse anti-SARS-CoV-N immune serum, and then incubated with Mouse-on-Mouse Polymer (Abcam, Cambridge, UK). The signal was developed with the DAB (3,3'-diaminobenzidine) substrate kit (Vector Laboratories). The nuclei were developed with Gill's haematoxylin before mounting the slides with VectaMount permanent mounting medium (Vector Laboratories). Images were acquired with the Olympus BX53 light microscope using 40×objective.

VeroE6 cells were maintained in DMEM with 10% FBS, 1% penicillin, and 1% streptomycin. The cells were seeded one day before the experiment at 2×10 5 cells per well in 12-well plates and were allowed to grow at 37 o C overnight. For the plaque assay, serially diluted samples were inoculated on the cells for 1h. Afterwards, 3% agarose/PBS was mixed with DMEM with 1.5% fetal bovine serum at a 1:2 ratio and applied to the cells. The cells were incubated for 96h for plaque formation. The plaques were visualized by staining the plates with 1% crystal violet in 20% ethanol/distilled water for 15min.

Cell lysate samples from the infected lung tissues were harvested at 2, 24, and 48hpi for qRT-PCR detection of mRNA levels of interferon (IFN) and cytokine/chemokine markers. Briefly, lung tissues were homogenised and lysed with RL buffer for RNA extraction using the RNeasy Mini kit (Qiagen). qRT-PCR was then performed using the QuantiNova SYBR RNase-free water, 0.2μl of QuantiNova SYBR Green RT-Mix, 1.6μl each of 10μM genespecific forward and reverse primer, and 4μl of extracted RNA as template. Reactions were incubated at 45°C for 10min for reverse transcription, 95°C for 5min for denaturation, followed by 45 cycles of 95°C for 5s and 55°C for 30s. Signal detection and measurement were taken in each cycle after the annealing step. The cycling profile ended with a cooling step at 40°C for 30s. The primer sequences are available upon requested.

Statistical analyses for the quantification of viral N antigen expression from SARS-CoV-2-or SARS-CoV-infected human lung tissues were performed with one-way ANOVA using GraphPad Prism 6 (GraphPad Software, Inc.). Statistical analyses for the area under the curve (AUC) comparison between SARS-CoV-2-and SARS-CoV-generated infectious virus particles from the infected human lung tissues were performed with Student's t-test using GraphPad Prism 6 as previously described. 15 Statistical analyses for SARS-CoV-2-or SARS-CoV-induced cytokine/chemokine expressions were performed with two-way ANOVA using GraphPad Prism 6. Differences were considered statistically significant when P<0.05.

A c c e p t e d M a n u s c r i p t 12 

A total of six patient donors were included in this study. These included 3 females and 3 males with a mean age of 53 years (range, 47-64 years) who underwent wedge resection or lobectomy for lung tumour. To evaluate their differential capacities to infect and replicate in human lung tissue, we inoculated human lung tissue explants with SARS-CoV-2 or SARS-CoV with an inoculum of 1×10 6 plaque-forming units per ml (PFU/ml) at 500µl per well. The Figure 2B , SARS-CoV-2 consistently demonstrated higher virus titer increases than that of SARS-CoV in lung tissues from all four donors. Our area under the curve (AUC) analysis revealed that SARS-CoV-2 generated 3.20 folds more infectious virus particles than that of SARS-CoV from the infected lung tissues over a period of 48h (P<0.024) ( Figure 2C ). Taken together, our results illustrated that SARS-CoV-2 was capable of infecting and replicating more robustly than SARS-CoV in human lung tissues.

To identify the cell types targeted by SARS-CoV-2 and SARS-CoV in the human lung, we performed immunohistochemistry staining of the virus-infected lung tissues ( Figures 3A to   3N ). Our results clearly demonstrated that SARS-CoV-2 could infect type I pneumocytes ( Figures 3A to 3C) , type II pneumocytes ( Figures 3E to 3H) , as well as alveolar macrophages ( Figure 3D ). In this regard, the cell tropism of SARS-CoV-2 in the human lung was similar to that of SARS-CoV, which also targeted types I and II pneumocytes (Figures 3I to 3J ) and alveolar macrophages ( Figure 3K to 3L). 

Using ex vivo human lung tissue explants respectively challenged by the same inoculum of SARS-CoV-2 and SARS-CoV, we showed that SARS-CoV-2 was more capable than SARS-CoV in infecting and replicating in human lung tissues. While both viruses infected type I and type II pneumocytes, and alveolar macrophages as target cells, the amount of viral N antigen expression in the virus-challenged lung tissues was significantly higher and more intensive in the tissues infected with SARS-CoV-2 than those infected with SARS-CoV.

Moreover, SARS-CoV-2 produced 3.20 folds higher amounts of infectious virus particles than that of SARS-CoV within 48 hpi. These findings might explain the high viral load in the respiratory secretions of COVID-19 patients during the early days on presentation or even during incubation, and thus its high person-to-person transmissibility. 4 Studies of SARS-CoV in cell culture suggested that its N protein antagonized IFNβ response in a dose-dependent manner. 22 Moreover, two other SARS-CoV proteins, namely Orf3b and Orf6, also antagonise IFN synthesis and signalling pathway. 23 While SARS-CoV-2 is also postulated to possess IFN antagonising proteins, the exact identities of these proteins remain undetermined at this stage. The differential degrees of IFN inhibition by these viruses' IFN antagonising proteins may explain the discrepant viral replications and inflammatory responses in human lungs observed in the present study. Moreover, most proinflammatory A c c e p t e d M a n u s c r i p t 16 cytokines and chemokines except IP10, a chemoattractant for monocytes/macrophages, T cells and NK cells, were more significantly induced by SARS-CoV than SARS-CoV-2. This finding may explain the more severe disease and higher mortality of SARS than that of COVID-19.

In contrast to SARS patients who had rising viral load in nasopharyngeal secretions that peaked at around day 10, the viral load in the respiratory secretions of COVID-19 patients peaked much earlier at the time of symptom onset. 21, 24 . The viral kinetics and innate immune response profiles in ex vivo human lung tissue characterised in this study might help to explain this observation. The suboptimally activated innate immune response would allow SARS-CoV-2 to replicate to high levels in the respiratory tract early on and may contribute to its efficient person-to-person transmission via droplets or contact with contaminated respiratory secretions containing high viral loads. 4, 21, 25 Notably, the higher degree of viral infection and replication of SARS-CoV-2 in human lung tissues corroborated with our recent finding that SARS-CoV-2 exhibited more efficient replication in Calu3 (human lung adenocarcinoma) cells than SARS-CoV. 15 Our findings have important implications on the infection control and treatment strategies for COVID-19 as SARS-CoV-2-infected patients may be infectious during the incubation period before onset of clinical symptoms due to its efficient suppression of host innate immune and proinflammatory response as evidenced by our findings. 26 

Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection

Coronavirus disease (COVID-19) Situation Report -74

Genomic characterization of the 2019 novel humanpathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Escalating infection control response to the rapidly evolving epidemiology of the Coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong

COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures

Epidemiology of Covid-19 in a Long-Term Care Facility in King County

Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures

Case-Fatality Risk Estimates for COVID-19 Calculated by Using a Lag Time for Fatality

Clinical Characteristics of Coronavirus Disease 2019 in China

Reinfection could not occur in SARS-CoV-2 infected rhesus macaques

The Pathogenicity of SARS-CoV-2 in hACE2

Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility

Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer

An observational study on the comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV: implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19

Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens

Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis

Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells

Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Is an Important Surface Attachment Factor That Facilitates Entry of Middle East Respiratory Syndrome Coronavirus

Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination

Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Presymptomatic Transmission of SARS-CoV-2

COVID-19 epidemic: disentangling the re-emerging controversy about medical facemasks from an epidemiological perspective

Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease

Effective Treatment of Severe COVID-19 Patients with Tocilizumab

A c c e p t e d M a n u s c r i p t 19 A c c e p t e d M a n u s c r i p t 20